Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...
Yahoo Finance1d
Merck & Co., Inc. (MRK)
MPM is a rare, aggressive cancer that forms in the lining of RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S ...
pharmaphorum11d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...
Business Insider8d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
The Two ACTive Immunotherapies-003 (TACTI-003) trial is an ongoing Phase IIb study (also known as KEYNOTE-C34) evaluating ...
Stockhouse20d
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret(TM) for the Treatment of Diabetic Macular Edema
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the Phase 2b/3 ...
Yahoo Finance26d
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.
Nasdaq19d
What's Wrong With Merck's Stock?
Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
Stockhouse13d
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company’s ...
FiercePharma26d
Merck's Keytruda flunks pivotal studies in early-stage lung and skin cancers
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.
STAT13d
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...
Merck & Co. Inc. stock underperforms Monday when compared to competitors
Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...